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Abstract 
 
Purpose: Fatigue is a debilitating symptom in cancer patients. It is believed that skeletal muscle 
wasting is a main cause of cancer related fatigue (CRF). As of now, there is no effective 
treatment of CRF. According to the 2009-2013 Research Agenda of the Oncology Nursing 
Society, a high priority in cancer research is symptom management. There is some evidence that 
nonsteriodal anti-inflammatory drugs (NSAIDs) reduce muscle wasting in tumor-bearing mice. 
The purpose of this study is to determine the effects of ibuprofen, an NSAID, on fatigue, muscle 
mass, and biomarkers of muscle protein breakdown in mice bearing the Lewis lung carcinoma. 
In mice, fatigue is measured as a decrease in voluntary wheel running activity (VMRA) relative 
to a baseline. Sample and methods: The sample is 24 adult, age-matched female C57BI/6 mice. 
The mice were acclimated to the cages and wheels for 7 days. On day one, half of the mice were 
inoculated with tumor cells and half served as healthy controls. Half of each group were 
implanted with a pellet designed to release 5 mg/kg/day Ibuprofen over the course of 21 days of 
tumor-growth or a placebo pellet. The 4 groups are tumor/placebo pellet, tumor/ibuprofen pellet, 
no tumor/placebo pellet, no tumor/ibuprofen pellet. VWRA, body weight, food and water intake 
were measured on days 0, 7, 14, and 19 of tumor growth. Mice were euthanized on day 20 and 
the gastrocnemius muscle was removed and weighed. Results: Ibuprofen had no significant 
effect on VWRA, muscle mass, or biomarkers of muscle protein degradation. There was a 
significant negative relationship between spleen size, an indicator of systemic inflammation, and 
muscle mass (-.53), and a significant positive relationship between spleen size and biomarkers of 
muscle protein degradation (.6), and between VWRA and muscle mass (.4). These data confirm 
that skeletal muscle wasting is related to inflammation, and muscle wasting contributes to 
fatigue.  More research is needed to develop effective interventions to reduce muscle wasting in 
patients with cancer-related fatigue. 
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Chapter 1: Statement of the Problem 
 
Introduction 
 
Cancer and its treatments generate symptoms that are difficult to live with. According to the 
National Cancer Institute, in 2007 there were over 11 million men and women alive with the 
history of cancer in the United States (Howlander 2010). According to the 2009-2013 Research 
Agenda of the Oncology Nursing Society, cancer symptom management is a priority. Quality of 
life is a paramount concern in the clinical management of cancer patients.  
Quality of life is negatively affected by the presence of cancer symptoms. One of the main 
symptoms with predominant effects on cancer patient’s lives is fatigue. Cancer Related Fatigue 
(CRF) manifests in 60-90% of cancer patients (Hauser 2008). Cancer related fatigue is not 
relieved by adequate sleep, proper nutrition, or a decrease in stressors. CRF can interfere with 
physical, psychosocial, economic, and occupational aspects of lives. This incurable fatigue 
significantly changes the life of a cancer patient. Currently, there is no effective and reliable 
treatment for CRF. 
 
Background     
 
“The National Comprehensive Cancer Network, defines cancer-related fatigue as a common, 
persistent, and subjective sense of tiredness related to cancer or to treatment for cancer that 
interferes with usual functioning” (Gupta 2007). CRF has been reported as the most difficult 
symptom to cope with by cancer patients. The impact of CRF on patients is devastating. (Wang 
2008). Cancer patients experience fatigue throughout cancer treatment, and long after the 
treatment is over (Wang 2008). This condition is most prevalent in patients with metastasized 
cancer or patients that are receiving multimodality or high dose treatment regimens. (Hauser 
2008). More aggressive treatment therapies and the increase in cancer survival have caused the 
prevalence of CRF to increase.  
The etiology of CRF is still unknown. There are several hypotheses being researched. Most 
research is directed towards the multifactoral nature of CRF, referred to as a “web of causation” 
(Wang 2008). CRF is associated with several other symptoms; however, there are no clear 
precipitating factors. One predominant explanation of CRF is the proinflammatory cytokine 
hypothesis. Chronic diseases cause a dysregulation in cytokine production. Elevated serum levels 
of inflammatory cytokines, namely, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-
a), have been related to persistent fatigue in cancer patients (Wang 2008).  
These cytokines are also known to cause skeletal muscle wasting. They are either produced 
by the tumor growth itself or the host response to the tumor growth. IL-6 and TNF-a are 
associated with skeletal muscle wasting in cancer (Hitt 2005). TNF-a increases the muscle 
expression of MAFbx and MuRF1, two biomarkers of muscle protein degradation via the 
ubiquitin-proteasome pathway (Acharyya 2004). TNF-a also increases the muscle expression of 
Bnip, a protein used in the autophagy of muscle cells (Hui Xu 2011). 
 Animal models provide a way to look at the biological mechanisms of muscle wasting, and 
provide a controlled environment to collect data. Previous studies have shown that tumor bearing 
mice show higher serum levels of pro-inflammatory cytokines than healthy controls (Argiles 
2007). This indicates the presence of inflammation. Mice treated with a non-steroidal anti-
inflammatory drug (NSAID) had decreased muscle wasting (Graves 2006) and decreased muscle 
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expression of MAFbx and receptors for TNF (Hitt, 2005). However, is it unknown if improved 
muscle mass and decreased inflammation will translate into reduced fatigue.  In mice, spleen 
enlargement is used as an indicator of inflammation. Fatigue is modeled as decreased locomotor 
activity or decreased voluntary wheel running activity (VWRA).  
 
Purpose of Study 
 
The purpose of this study is to determine the effects of ibuprofen, an NSAID, on fatigue, muscle 
mass, spleen size, and muscle expression of MurF1, MAFbx, and Bnip, biomarkers of muscle 
protein breakdown in female mice bearing the Lewis lung carcinoma. We hypothesize that: 
 
1) Ibuprofen will preserve muscle mass in tumor-bearing mice.  
 
2) Ibuprofen will reduce spleen size in tumor-bearing mice. 
 
3) Muscle mass will be related to VWRA. 
 
4) Ibuprofen will reduce expression of biomarkers of protein breakdown in muscle tissue of 
tumor-bearing mice.  
 
Significance 
  
CRF is difficult for patients and health care providers to manage. More reliable and consistent 
treatments are needed to control this devastating experience for cancer patients. Previous studies 
have shown that ibuprofen decreases muscle wasting in tumor-bearing mice.  This experiment 
will determine if ibuprofen has an effect on VWRA in this animal model of CRF.  The data from 
this study will increase our understanding of CRF and contribute to the development of effective 
treatments for this devastating symptom in cancer patients.  
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Chapter 2: Literature Review 
 
CRF is a debilitating symptom experienced by up to 90% of cancer patients. CRF is universal 
among all types of cancer and more prevalent in advanced cancer. It is associated with poor 
quality of life, and reduced ability to perform activities of daily living (Hauser 2008). The 
physical symptoms interact with the emotional symptoms, affecting the patient’s perception of 
disease and ability to cope (Wang 2008). In a study done by Hauser et. al (2008) on the 
prevalence, severity and characteristics of CRF, patients reported inability to complete important 
activities and described fatigue as more distressing than pain, nausea, and vomiting.  
Pathophysiology of CRF has not been adequately elucidated. Possible causes of CRF include 
the cancer itself as well as the treatments and symptoms that are commonly clustered with 
fatigue. Factors known to occur with or contribute to CRF include pain, emotional distress, sleep 
disturbance, anemia, nutritional deficiencies, cardiac deconditioning, and co-morbidities. 
However, the factor that is both necessary and sufficient to induce development of CRF has not 
yet been identified (Wang 2008). The interaction of etiology and host response creates a 
complicated chain of possible causalities.  
Potential causes are grouped into disease related and treatment related factors. For instance, 
surgical procedures have been known to induce fatigue. Post-operative fatigue can be related to 
several factors such as anesthesia, analgesics, decreased ventilation capacity, immobilization, 
infection, or anxiety. Chemotherapy is also a treatment known to cause fatigue. Common co-
existing symptoms of chemotherapy such as anemia, nausea, vomiting, and diarrhea can cause 
patients to experience CRF. CRF may also be associated with accumulated byproducts of 
apoptosis that occurs during chemotherapy. Fluctuations in fatigue have been noted throughout 
the course of chemotherapy. Neurotoxic effects of chemotherapy drugs also present as a potential 
causative factor.  Patients have reported that fatigue is experienced more when they are close to 
their white blood cell nadir, the time when their white blood cell count is the lowest. Patients 
report that the fatigue decreases as the white blood cell count improves (Wang 2008). Another 
cancer treatment that is known to cause fatigue is radiotherapy. The side effects of radiotherapy 
are all potential precursors to fatigue; they include anemia, diarrhea, weight loss, anorexia, and 
chronic pain. Biological-response modifiers are known to cause such intense fatigue that 
treatments must be stopped. Some types cause up to 70% of the recipients to experience intense 
fatigue. Tumor related factors are potential causes as well. Patients with advanced stages of 
cancer experience more intense fatigue because the progressing tumor and disease have severe 
effects on several organ systems (Wang 2008). 
      There are several hypothesized mechanisms of CRF. An organizing hypothesis is the 
dysregulation of pro-inflammatory cytokines. Pro-inflammatory cytokines affect normal muscle 
function. Neurophysiologic changes in skeletal muscles have been noted in previous studies 
(Wang 2008). Cytokines also affect the metabolic process in muscles, causing them to become 
weak. Skeletal muscle wasting is induced by pro-inflammatory cytokines. Growing evidence 
shows the important role that pro-inflammatory cytokines such as IL-6 and TNFa have in tumor-
induced muscle wasting (Argiles 2009, Tisdale 2009). TNF-a is produced by the host immune 
cells in response to the tumor and has a significant role in tumor-induced muscle wasting. IL-6 
and TNFa are associated with increased expression of the ubiquitin-proteasome pathway (UPP) 
of muscle protein degradation and autophagy in skeletal muscle. The ubiquitin-proteasome is one 
of three proteolytic pathways in muscles. UPP takes part in muscle myofilament break down. 
Animal and human models of muscle wasting show that the UPP contributes to the degradation 
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of myofibrillar proteins (Tisdale 2009). Increased activity of the UPP is associated with 
increased expression of MuRF1 and MAFbx which are two muscle-specific E3 ubiquitin ligases 
that mark myosin protein for degradation by the proteasomes (Achaeyya 2004). The expression 
of MuRF1 and MAFbx has been shown to increase in animal models of muscle wasting (Dodson 
2011). The cytokines also increase expression of Bnip, a protein that is necessary for the 
formation of vesicles for autophagic degradation of intracellular proteins (Hui Xu 2011). 
Structural changes in the muscle fiber make the muscle more susceptible to fatigue during 
exercise, which is modeled as decreased VWRA in a mouse model. Proinflammtory cytokines 
also increase expression of cyclo-oxygenase (COX) (Hitt 2005). NSAIDs block the COX-1 and 
COX-2 activity, and have been shown to reduce muscle wasting, and reduce the expression of 
MAFbx and receptors for TNF in muscle tissue of tumor-bearing mice. NSAIDs may preserve 
muscle mass by reducing muscle response to the catabolic effects of TNF-a (Graves 2006).  
The multifactoral and multidimensional nature of CRF has hindered the development of 
CRF methodologies. The relationship between pathophysiology and host susceptibility exposes a 
complex web of causation. Limitations also arise from the differences in patient disease 
processes and variation in fatigue measurement techniques (Gupta 2006). The inherent 
subjectivity of CRF has hindered the development of pre-clinical models (Wang 2008). Animal 
models have been used to study CRF because it provides a more controlled environment to 
gather data from. Rodents are nocturnal animals and will normally run 2-3 miles during the 
night. In mice, decreased VWRA indicates illness-induced fatigue (Skinner 2009). 
 
Chapter 3: Methods 
 
Introduction 
 
This study used a quantitative, experimental design with random assignment of adult, age-
matched female C57BI/6 mice to one of four treatment groups:  tumor, tumor plus ibuprofen, no 
tumor, no tumor no ibuprofen. The mice were housed in their own cages with food and water 
available at all times. Lewis lung carcinoma (LLC) cells obtained from American Type Tissue 
Culture (Manassa, VA, USA) were used to induce tumor growth. Mice were inoculated with 
tumor cells on day one. Body weight, food and water intake, and VWRA were measured on days 
0, 7, 14, and 19 of tumor growth. Mice were euthanized on day 20.  
 
Procedure 
 
The mice were acclimated to the cages and wheels for 7 days. Running wheels were 
removed from the cages after the acclimation period. On day one, half of the mice were 
inoculated with tumor cells and half served as healthy controls. The tumor mice were inoculated 
subcutaneously between the scapulae with 5x10^5 LLC tumor cells in .2ml of saline. The control 
mice were injected subcutaneously between the scapulae with .2ml of saline. Half of each group 
was implanted with a pellet designed to release 5 mg/kg/day ibuprofen over the course of 21 
days of tumor-growth or a placebo pellet. Body weight, food, and water intake were measured on 
days 0, 7, 14, and 19 of tumor growth. On days 0,7,  14, and 19 wheels were put into the cages 
and VWRA was monitored for 24 hours. Mice were sacrificed on day 20 and weighed. The 
gastrocnemius muscle and spleen were removed and weighed. The samples were wrapped in foil, 
frozen in liquid nitrogen, and stored at -80 degrees. Weights of right and left gastrocnemius 
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muscles were averaged to determine muscle weight. Muscle mass was determined by dividing 
muscle weight by the body weight. Total RNA was extracted from 100mg of frozen gastroc 
muscle in TRIzol (Invitrogen, Carlsbad, CA). RNA was treated with DNase 1 (Invitrogen) and 
reverse transcribes to cDNA using the Iscipt cDNA synthesis kit (BioRad). Real time PCR was 
performed using primer pairs for MAFbx and MuRF1. Bnip was detected using a TaqMan Gene 
Expression Assay according to manufacturer’s instruction.  
 
Voluntary Wheel Running Activity 
 
VWRA was measured to indicate the presence of illness related fatigue in mice. Healthy 
mice run from 2-3 miles a night (Skinner 2009).  Running wheels were obtained from Columbus 
Instruments in Columbus Ohio.  Wheel turns were counted by a magnetic switch mounted 
outside of the cage that is triggered by a magnet imbedded in the front of the wheel. The 
mechanical switches are connected to a cable that plugs into an input module. The boxes are 
connected to an external computer programed to record the data at preset intervals. Baseline 
VWRA was recorded on day 0 for each mouse before tumor induction. VWRA was recorded on 
days 7, 14, and 19 of tumor growth.  
 
Drug Treatment 
 
        The Ibuprofen pellets were obtained from Innovative Research of American (Sarasota 
Florida). They are designed to release the drug slowly at 5mg/kg/day. Half of the tumor mice and 
half of the control mice received a drug pellet and half received a same-sized placebo pellet. The 
pellets were placed in the subcutaneous space on the right flank of the mice. The mice were 
lightly anesthetized with inhaled isofluorane and the fur was shaved and cleaned with 70% 
ethanol. The pellet was inserted using a sterile trochar needle. The incision was closed with 
dermaglue. Antibiotic ointment was applied to the incision site.  
 
Data Analysis 
  
         Data was entered into a spread sheet and analyzed using SPSS 16. The independent 
variables were tumor and drug. The dependent variables were muscle mass, spleen weight, 
VWRA, and relative expression of Bnip, MAFbx and MURF mRNA in muscle tissue. Data was 
analyzed using a two way ANOVA to determine main effects of the independent variables on 
each dependent variable. Bivariate correlations between dependent variables were also 
examined.  
 
Chapter 4:  
 
Results 
      
        There was no main effect of tumor or drug treatment on muscle mass. Thus, there were no 
overt signs of cachexia in the tumor-bearing mice.  
 
Cancer Related Fatigue   Dan 8 
 
There was a main effect of tumor on spleen weight (p=.000) and a main effect of drug treatment 
on spleen weight (p=.000).Thus, tumor growth induced an inflammatory response, and ibuprofen 
reduced the inflammation.  There was no main effect of tumor or drug treatment on VWRA. 
Thus, neither tumor growth nor drug treatment affected locomotor activity of the mice.  
However, there were equipment failures during each session of recording of VWRA. There was 
a main effect of tumor on muscle expression of MAFbx (p=.031), but there was no effect of drug 
treatment. There was no main effect of tumor or drug treatment on muscle MuRF1. There was a 
significant tumor effect on muscle expression of Bnip (p=.012) and a significant effect of drug 
treatment on Bnip (p=.047). Thus, tumor growth increased expression of MAFbx and Bnip, two 
biomarkers of muscle protein degradation, but only Bnip was reduced by treatment with 
ibuprofen.  
 
There was a significant positive correlation between spleen size, and muscle expression of 
MAFbx (r=.72, p=.000), MuRF1 ( r=.56, p=.005) and Bnip mRNA (r=.61, p=.002), supporting 
the idea that inflammation contributed to muscle protein degradation. There was a correlation 
between VWRA and muscle mass, suggesting that muscle wasting contributes to fatigue (r=.4, 
p=.011).There was a significant negative relationship between spleen size and muscle mass (r= -
.53, p<.001), indicating that the inflammation contributed to smaller muscle mass.  
 
Significant Correlations  
 Spleen VWRA  MAFbx MuRF1 Bnip 
Spleen 1 -.5 .7 .5 .6 
Muscle Mass -.5 .4    
 
   These data confirm that skeletal muscle wasting is related to inflammation, and muscle wasting 
is related to fatigue.  The reduced spleen size in mice treated with ibuprofen verifies that 
ibuprofen did reduce inflammation in the tumor-bearing mice, and reduced expression of a 
biomarker of authophagy, though it did not affect muscle mass directly. 
 
Chapter 5: 
 
Summary of Findings 
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       CRF is present in 60-90% of cancer patients and is repeatedly reported as the most 
debilitating symptom by cancer patients. It reduces quality of life and contributes to cancer 
morbidity. The multifactorial nature of CRF has made it difficult to discover an effective method 
of management. Palliative care and symptom management are essential in preserving the quality 
of life for cancer patients. Currently, there are no reliable treatments of CRF. Previous research 
has shown that ibuprofen, an NSAID, preserved muscle mass in tumor bearing mice (Graves 
2005). This research was performed to explore the effects of ibuprofen on fatigue in tumor 
bearing mice. Fatigue in mice is modeled as a decrease in VWRA. In the present study, we failed 
to demonstrate an effect of tumor growth or ibuprofen on the gastrocnemius muscles of the 
tumor bearing mice nor their VWRA. However, tumor growth and drug treatment showed 
significant effects on spleen weight. The spleens of the tumor bearing mice were significantly 
larger than the control group, and were reduced by treatment with ibuprofen.   This reduction in 
spleen size was accompanied by the reduced expression of MAFbx and Bnip in muscles of tumor 
bearing mice treated with ibuprofen.   
 
Conclusions 
 
       Ibuprofen produced an anti-inflammatory effect indicated by a decrease in spleen weight of 
the tumor-bearing mice. Ibuprofen also decreased expression of Bnip mRNA in gastrocnemius 
muscles of  tumor-bearing mice. However, ibuprofen had no effect on muscle mass or VWRA of 
the tumor-bearing mice.  It should be noted that expression of MAFbx and Bnip mRNA was 
increased in muscles of tumor-bearing mice, which suggests that wasting may have occurred had 
the study duration been longer.  We were unable to obtain reliable group measures of VWRA on 
days 0, 7, and 14, with failure of data collection on day 19. However, muscle mass was 
correlated with VWRA on day 14, supporting the idea that muscle wasting contributes to CRF. 
Further research is needed to develop a better understanding of the pathology of CRF and to 
discover effective interventions to preserve muscle mass and reduce fatigue in cancer patients. 
Improving the understanding of the nature of CRF can ultimately lead to more effective 
management regimens. When pathophysiologic mechanisms are better understood, clinical 
studies should be performed to improve CRF detection and treatment. The only effective way to 
battle CRF is from a multidisciplinary approach.  
 
 
 
 
 
 
 
Cancer Related Fatigue   Dan 10 
 
References 
Acharyya, S., Lander, K.J., Nelson, L.L., Damrauer, J., Reiser, P.J., Swoap, S., Guttridge, D.C. 
(2004). Cancer Cachexia is Regulated by Selective Targeting of Skeletal Muscle Gene 
Products. The Journal of Clinical Investigation, 114 (3), 370-378. 
Al-Majid, Sadeeha, and Haidee Waters. (2008).The Biological Mechanisms of Cancer-Related 
Skeletal Muscle Wasting: The Rule of Progressive Resistance Exercise. Biological 
Research for Nursing, 7-19. 
Argiles, J.M., Lopez-Soriano, F.J., Busquets, S. (2007). Mechanisms to Explain Wasting of              
Muscle and Fat in Cancer Cachexia. Current Opinion in Supportive Care, 1, 293-298. 
Dodson, S., Baracos, V.E., Jatoi, A., Evans, W.J., Cella, D., Dalton, J.T., Steiner, M.S. (2011). 
Muscle Wasting in Cancer Cachexia: Clinical Implication, Diagnosis, and Emerging 
Treatment Strategies. The Annual Review of Medicine.  
 
Graves, E., Ramsay, E., McCarthy, D.O. (2006). Inhibitors of COX Activity Preserve Muscle 
Mass in Mice Bearing the Lewis Lung Carcinoma, but not the B16 Melanoma. Research 
in Nursing and Health, 29, 87-97. 
 
Gupta, D., Lis, C.G., Grutsch, J.F. (2007).The Relationship Between Cancer-Related Fatigue and 
Patient Satisfaction with Quality of Life in Cancer. Journal of Pain and Symptom 
Management, 34, 40-47. 
 
Hauser, K., Walsh, D., Rybicki, L.A., Davis, M.P., Seyidova-Khoshknabi, D. (2008). Fatigue in 
advanced Cancer: A prospective Study. American Journal of Hospice and Palliative 
Medicine, 25 (5), 372-378. 
 
Hitt, A., Graves, E., McCarthy, D.O. (2005). Indomethacin Preserves Muscle Mass and Reduces 
Levels of E3 Ligases and TNF Receptor Type I in the Gastrocnemius Muscle of Tumor-
bearing Mice. Research in Nursing and Health, 28, 56-66. 
 
Howlader N., Noone A.M., Krapcho M., Neyman N., Aminou R., Waldron W., Altekruse S.F., 
Kosary C.L., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Eisner M.P., Lewis D.R., Chen 
H.S., Feuer E.J., Cronin K.A., Edwards B.K. SEER Cancer Statistics Review, 1975-2008,  
Hui, X., Crawford, D., Hutchinson, K.R., Youtz, D.J., Lucchesi, P.A., Velten, M., McCarthy, 
D.O., Wold, L.E. (2011). Myocardial Dysfunction in an Animal Model of Cancer 
Cachexia. Life Styles, 88, 406-410. 
 
National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on 
November 2010 SEER data submission, posted to the SEER web site, 2011. 
 
Reid, J., McKenna, H., Fitzsimons, D., McCane, T. (2009). The Experience of Cancer Cachexia: 
A Qualitative Study of Advanced Cancer Patients and their Family Members. 
International Journal of Nursing Studies, 46, 606-616.  
Cancer Related Fatigue   Dan 11 
 
 
Skinner, G.W., Duncan,M., Harden, L.M. (2009). Avoidance of Physical Activity is a Sensitive 
Indicator of Illness, 96, 421-427. 
 
Tisdale, M.J. (2009). Mechanisms of Cancer Cachexia. The American Physiology Review 
Society, 89, 381-410. 
 
Wang, X. S. (2008). Pathophysiology of Cancer-Related Fatigue. Clinical Journal of Oncology 
Nursing, 12 (5), 11-20. 
 
 
 
 
 
 
 
 
